259 related articles for article (PubMed ID: 18098139)
1. Growth phenotypes and biosafety profiles in poliovirus-receptor transgenic mice of recombinant oncolytic polio/human rhinoviruses.
Cello J; Toyoda H; Dejesus N; Dobrikova EY; Gromeier M; Wimmer E
J Med Virol; 2008 Feb; 80(2):352-9. PubMed ID: 18098139
[TBL] [Abstract][Full Text] [Related]
2. A host-specific, temperature-sensitive translation defect determines the attenuation phenotype of a human rhinovirus/poliovirus chimera, PV1(RIPO).
Jahan N; Wimmer E; Mueller S
J Virol; 2011 Jul; 85(14):7225-35. PubMed ID: 21561914
[TBL] [Abstract][Full Text] [Related]
3. Polypyrimidine tract binding protein-1 (PTB1) is a determinant of the tissue and host tropism of a human rhinovirus/poliovirus chimera PV1(RIPO).
Jahan N; Wimmer E; Mueller S
PLoS One; 2013; 8(4):e60791. PubMed ID: 23593313
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model.
Toyoda H; Yin J; Mueller S; Wimmer E; Cello J
Cancer Res; 2007 Mar; 67(6):2857-64. PubMed ID: 17363609
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus.
Ochiai H; Campbell SA; Archer GE; Chewning TA; Dragunsky E; Ivanov A; Gromeier M; Sampson JH
Clin Cancer Res; 2006 Feb; 12(4):1349-54. PubMed ID: 16489093
[TBL] [Abstract][Full Text] [Related]
6. Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme.
Goetz C; Gromeier M
Cytokine Growth Factor Rev; 2010; 21(2-3):197-203. PubMed ID: 20299272
[TBL] [Abstract][Full Text] [Related]
7. Age-dependent poliovirus replication in the mouse central nervous system is determined by internal ribosome entry site-mediated translation.
Kauder S; Kan S; Racaniello VR
J Virol; 2006 Mar; 80(6):2589-95. PubMed ID: 16501069
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of IRES-mediated, cell-type-specific cytotoxicity of poliovirus using a colorimetric cell proliferation assay.
Yang X; Chen E; Jiang H; Muszynski K; Harris RD; Giardina SL; Gromeier M; Mitra G; Soman G
J Virol Methods; 2009 Jan; 155(1):44-54. PubMed ID: 18951922
[TBL] [Abstract][Full Text] [Related]
9. Development of candidates for new type 2 and type 3 oral poliovirus vaccines.
Kohara M; Abe S; Yoshioka I; Nomoto A
Dev Biol Stand; 1993; 78():141-8. PubMed ID: 8388824
[TBL] [Abstract][Full Text] [Related]
10. Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype.
Rezapkin GV; Fan L; Asher DM; Fibi MR; Dragunsky EM; Chumakov KM
Virology; 1999 May; 258(1):152-60. PubMed ID: 10329577
[TBL] [Abstract][Full Text] [Related]
11. Studies on neurovirulence in poliovirus-sensitive transgenic mice and cynomolgus monkeys for the different temperature-sensitive viruses derived from the Sabin type 3 virus.
Abe S; Ota Y; Doi Y; Nomoto A; Nomura T; Chumakov KM; Hashizume S
Virology; 1995 Jun; 210(1):160-6. PubMed ID: 7793068
[TBL] [Abstract][Full Text] [Related]
12. Genetic determinants of cell type-specific poliovirus propagation in HEK 293 cells.
Campbell SA; Lin J; Dobrikova EY; Gromeier M
J Virol; 2005 May; 79(10):6281-90. PubMed ID: 15858012
[TBL] [Abstract][Full Text] [Related]
13. The double-stranded RNA binding protein 76:NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site.
Merrill MK; Gromeier M
J Virol; 2006 Jul; 80(14):6936-42. PubMed ID: 16809299
[TBL] [Abstract][Full Text] [Related]
14. Expression of mutated poliovirus receptors in human neuroblastoma cells persistently infected with poliovirus.
Pavio N; Couderc T; Girard S; Sgro JY; Blondel B; Colbère-Garapin F
Virology; 2000 Sep; 274(2):331-42. PubMed ID: 10964776
[TBL] [Abstract][Full Text] [Related]
15. Will the polio niche remain vacant?
Rieder E; Gorbalenya AE; Xiao C; He Y; Baker TS; Kuhn RJ; Rossmann MG; Wimmer E
Dev Biol (Basel); 2001; 105():111-22; discussion 149-50. PubMed ID: 11763320
[TBL] [Abstract][Full Text] [Related]
16. The molecular basis of poliovirus neurovirulence.
Ohka S; Nomoto A
Dev Biol (Basel); 2001; 105():51-8. PubMed ID: 11763337
[TBL] [Abstract][Full Text] [Related]
17. [Mouse neurovirulence of antigenic chimeras (type I/II) of polioviruses].
Dai C
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1993 Feb; 15(1):34-8. PubMed ID: 7686824
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of vaccine-derived polioviruses in stools of immunodeficient children in South Africa.
Pavlov DN; Van Zyl WB; Van Heerden J; Kruger M; Blignaut L; Grabow WO; Ehlers MM
J Appl Microbiol; 2006 Dec; 101(6):1367-79. PubMed ID: 17105568
[TBL] [Abstract][Full Text] [Related]
19. A poliomyelitis model through mucosal infection in transgenic mice bearing human poliovirus receptor, TgPVR21.
Nagata N; Iwasaki T; Ami Y; Sato Y; Hatano I; Harashima A; Suzaki Y; Yoshii T; Hashikawa T; Sata T; Horiuchi Y; Koike S; Kurata T; Nomoto A
Virology; 2004 Mar; 321(1):87-100. PubMed ID: 15033568
[TBL] [Abstract][Full Text] [Related]
20. Efficient delivery of circulating poliovirus to the central nervous system independently of poliovirus receptor.
Yang WX; Terasaki T; Shiroki K; Ohka S; Aoki J; Tanabe S; Nomura T; Terada E; Sugiyama Y; Nomoto A
Virology; 1997 Mar; 229(2):421-8. PubMed ID: 9126254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
